Target Information

Target General Infomation
Target ID
T45597
Target Name
S6K kinase
Target Type
Clinical Trial
Disease Cancer [ICD9: 140-229; ICD10: C00-C96]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
BioChemical Class
Transferases (EC:2)
EC Number
EC 2.7.11.1
Drugs and Mode of Action
Drug(s) LY-2584702 Drug Info Phase 1 Cancer [523253], [543009]
LY2780301 Drug Info Phase 1 Cancer [523025]
LYS-6KAKT1 Drug Info Phase 1 Cancer [549276]
MSC2363318A Drug Info Phase 1 Solid tumours [524495]
XL418 Drug Info Phase 1 Solid tumours [522010]
Modulator LY-2584702 Drug Info
LY2780301 Drug Info [533217]
LYS-6KAKT1 Drug Info
MSC2363318A Drug Info [524495]
XL418 Drug Info
References
Ref 522010ClinicalTrials.gov (NCT00460278) Study of XL418 in Adults With Solid Tumors. U.S. National Institutes of Health.
Ref 523025ClinicalTrials.gov (NCT01115751) A Study in Patients With Advanced or Metastatic Cancer. U.S. National Institutes of Health.
Ref 523253ClinicalTrials.gov (NCT01241461) A Study of LY2584702 in Solid Tumors. U.S. National Institutes of Health.
Ref 524495ClinicalTrials.gov (NCT01971515) First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
Ref 543009(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8248).
Ref 549276Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034531)
Ref 524495ClinicalTrials.gov (NCT01971515) First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies. U.S. National Institutes of Health.
Ref 533217A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.